文献速递胰腺与胆道疾病消化内镜肝病

他克莫司与吲哚美辛降低肝移植后ERCP胰腺炎风险

Tacrolimus and Indomethacin Are Safe and Effective at Reducing Pancreatitis After Endoscopic Retrograde Cholangiopancreatography in Patients Who Have Undergone Liver Transplantation.
PubMed 文献 · Clin Gastroenterol Hepatol · 2019-10-14

本研究回顾性分析337例肝移植后因胆道并发症行ERCP的患者(共937次操作),发现他克莫司谷浓度>2.5 ng/mL与PEP风险降低79%相关,直肠吲哚美辛与风险降低91%相关;两者联用进一步降低PEP风险93%,且吲哚美辛不增加出血、胆管炎或肾功能恶化风险。

要点

  • 他克莫司谷浓度>2.5 ng/mL与ERCP后胰腺炎风险降低79%独立相关。
  • 直肠吲哚美辛使ERCP后胰腺炎风险降低91%,且不增加出血或胆管炎。
  • 他克莫司谷浓度>2.5 ng/mL时加用吲哚美辛,PEP风险进一步降低93%。

核心结论

  • 肝移植后因胆道并发症行ERCP的患者中,他克莫司谷浓度>2.5 ng/mL显著降低PEP风险。
  • ERCP后直肠给予吲哚美辛显著降低胰腺炎发生率,并在使用他克莫司的患者中进一步降低风险。
  • 两药联用可防止患者发生中重度胰腺炎,且吲哚美辛不加重慢性肾病患者的肾功能。

研究设计与样本

  • 回顾性研究纳入2007年6月1日至2015年12月1日肝移植后因胆道并发症行ERCP的337例患者,共937次操作。
  • 2012年6月1日后常规在ERCP结束时给予直肠吲哚美辛100 mg(除非有禁忌),共286次操作后使用。
  • 排除急慢性排斥反应后,323例患者维持稳定他克莫司剂量,共901次操作纳入分析。
  • 采用混合效应多因素logistic回归计算他克莫司和吲哚美辛与PEP风险的校正OR。

主要发现

  • PEP发生于2.2%的ERCP操作后。
  • 他克莫司谷浓度>2.5 ng/mL与PEP风险降低79%相关(OR 0.21;95% CI 0.06-0.72;P=0.01)。
  • 吲哚美辛未影响出血率、胆管炎发生率或肾小球滤过率下降。

关键数值与推荐

  • 他克莫司谷浓度阈值:>2.5 ng/mL。
  • 直肠吲哚美辛剂量:100 mg,于ERCP结束时给药。
  • 主要结局为PEP发生;次要结局包括中重度PEP、胆管炎和出血。

临床怎么用

  • 肝移植后ERCP患者应关注他克莫司谷浓度,>2.5 ng/mL可能有助于降低PEP风险。
  • 无禁忌时可考虑ERCP后直肠给予吲哚美辛100 mg以降低PEP风险。
  • 他克莫司谷浓度>2.5 ng/mL的患者加用吲哚美辛可进一步降低PEP风险。
  • 慢性肾病患者使用吲哚美辛未观察到肾功能恶化,但仍需个体化评估。

局限性

  • 回顾性研究设计。
  • 单中心数据。
  • 吲哚美辛为2012年后常规使用,存在时间趋势偏倚可能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Biliary complications occur in up to 25% of patient following liver transplantation and are often managed by endoscopic retrograde cholangiopancreatography (ERCP). Pancreatitis is the most common adverse event after ERCP (PEP). Tacrolimus and rectal indomethacin have each been reported to reduce risk of PEP. We investigated the incidence of PEP in patients who have undergone ERCP after liver transplantation and the effectiveness of tacrolimus and/or indomethacin in reducing risk of PEP. METHODS: We performed a retrospective study of 337 patients who underwent ERCP (n = 937 procedures) for biliary complications after liver transplantation from June 1, 2007 through December 1, 2015. After June 1, 2012, rectal indomethacin (100 mg) was routinely administered at the conclusion of the ERCP unless patients had contraindications. Indomethacin was given after 286 ERCP procedures. After excluding patients with acute/chronic rejection, 323 patients were maintained on a stable dose of tacrolimus prior to ERCP (901 procedures). We collected data on demographic and clinical variables, pre-procedural tacrolimus trough levels, and development of PEP. We calculated adjusted odds ratios (ORs) for the association between tacrolimus and indomethacin use and risk of PEP using mixed-effects multivariable logistic regression. The primary outcome was development of PEP; secondary outcomes included the development moderate-to-severe PEP, cholangitis and bleeding. RESULTS: PEP occurred after 2.2% of ERCP procedures. A trough level of tacrolimus above 2.5 ng/mL was associated with 79% lower odds of PEP (OR, 0.21; 95% CI, 0.06-0.72; P = .01). Indomethacin was associated with a 91% reduction in risk of PEP (OR, 0.09; 95% CI, 0.01-0.85; P = .03). Indomethacin use did not affect rates of bleeding or cholangitis or decrease in glomerular filtration rate. In patients with trough levels of tacrolimus above 2.5 ng/mL, addition of indomethacin reduced the odds of PEP by 93% compared with patients who were unexposed to indomethacin. (OR, 0.07; 95% CI, 0.01-0.90; P = .04). CONCLUSIONS: In a retrospective study of patients who underwent ERCP for biliary complications after liver transplantation, we found trough levels of tacrolimus above 2.5 ng/mL to significantly reduce risk for PEP. Rectal administration of indomethacin after ERCP significantly decreased rates of pancreatitis, and reduced risk further in patients given tacrolimus. Administration of both drugs prevented patients from developing moderate or severe pancreatitis. Indomethacin did not worsen renal function in patients with chronic kidney disease.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Thiruvengadam NR, Forde KA, Chandrasekhara V, et al. Tacrolimus and Indomethacin Are Safe and Effective at Reducing Pancreatitis After Endoscopic Retrograde Cholangiopancreatography in Patients Who Have Undergone Liver Transplantation. Clin Gastroenterol Hepatol. 2019. PMID: 31622734. doi:10.1016/j.cgh.2019.10.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。